BB Good human data, but mixed outcomes or surrogate markers. How we grade →Pharmacokinetic RCT (crossover) · Healthy men
Repeated administration of berberine inhibits cytochromes P450 in humans
Y Guo, Y Chen, ZR Tan, CD Klaassen, HH Zhou. European Journal of Clinical Pharmacology. 2012.
Bottom line: In healthy men, 2 weeks of berberine at 300 mg three times daily slowed three major drug-processing enzymes, raising the potential for interactions with common medications.
- In plain language
- Healthy men took berberine (300 mg three times a day) or placebo for 2 weeks in a randomized crossover study, then received probe drugs that measure the activity of five liver enzymes that process medications. Berberine reduced CYP2D6 activity (the dextromethorphan urinary ratio rose ninefold) and CYP2C9 activity (the losartan ratio doubled). It also reduced CYP3A4 activity: blood exposure (AUC) to midazolam rose about 40%, peak levels rose 38% and midazolam clearance fell 27%. Berberine had no significant effect on the probe drugs for CYP2C19 and CYP1A2.
- Limits
- The study was small and included only healthy men, and the abstract does not report the number of participants. It used single doses of probe drugs, not real-world medication regimens, and lasted only 2 weeks.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Berberine dose, side effects and drug interactions: what the trials used and who should skip it
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Berberine and glucose metabolism
- CC Small or few human trials. Promising, not proven. How we grade →Ratings card: Berberine HCl: Healthy glucose metabolism
- Source
- doi.org/10.1007/s00228-011-1108-2 · PubMed 21870106
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. Reviewed . We sell some of what we grade.